Close
Gregory Ruehlmann is a partner in the Atlanta office and a member of the firm’s Trial practice, where he focuses on high-profile product-liability, class-action, and other mass-tort litigation.
Gregory has developed considerable experience in nationwide defense of Fortune 500 companies in the medical-device, automotive, pharmaceutical, and consumer-product sectors at all stages of litigation—from initial assessment and case strategy to offensive and defensive discovery and deposition-taking up to and including working on multiple core trial teams. Gregory has served as the lead drafter on several successful dispositive motions and Daubert challenges, but is equally focused on developing the themes, facts, and testimony necessary for victory at trial.
In addition to tort and product-liability work, Mr. Ruehlmann has experience in litigating a wide range of business and trademark disputes and conducting internal investigations. He also maintains a pro bono practice by representing asylum clients with the Georgia Asylum and Immigration Network (GAIN).
Publications
- Managing editor, The Regulation of Pharmaceutical Manufacturers (3d ed.), Fastcase
- Co-author of “The Trial of a Drug or Device Case,” in Drug & Device Product Liability Litigation Strategy (2d ed. 2018), Oxford Univ. Press
- Co-author of “Recalling an Expert Witness in ‘Rebuttal’,” Bloomberg Law’s Expert Evidence Report (2018)
- “‘A Deposition Is Not a Take Home Examination’: Fixing Federal Rule 30(e) and Policing the Errata Sheet,” 106 Northwestern Univ. Law Review 893 (2012)
back
